Literature DB >> 18587261

Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.

Franco Di Silverio1, Alessandro Sciarra, Ulderico Parente, Alfarone Andrea, Magnus Von Heland, Valeria Panebianco, Roberto Passariello.   

Abstract

A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy. After sorafenib treatment and before surgery a new CT scan confirmed the presence of a 9.0 cm in diameter solid mass in the left kidney but a reduction in thrombus extension, limited to the left renal vein. At histological examination after radical nephrectomy, over 90% of the renal mass was substituted by necrotic tissue. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587261     DOI: 10.1159/000132708

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  10 in total

Review 1.  [Systemic and surgical management of metastatic renal cell carcinoma].

Authors:  M W Kramer; A S Merseburger; I Peters; S Waalkes; M A Kuczyk
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 2.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

3.  Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: A clinical study.

Authors:  Gang Guo; Wei Cai; Hongzhao Li; Jiangping Gao; Xin Ma; Jun Dong; Weijun Fu; Xu Zhang
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

4.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

Review 5.  Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.

Authors:  Aristotle Bamias; Bernard Escudier; Cora N Sternberg; Flora Zagouri; Athanasios Dellis; Bob Djavan; Kimon Tzannis; Loukas Kontovinis; Konstantinos Stravodimos; Athanasios Papatsoris; Dionysios Mitropoulos; Charalampos Deliveliotis; Meletios-Athanasios Dimopoulos; Constantine A Constantinides
Journal:  Oncologist       Date:  2017-06-07

Review 6.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20

7.  Tumor thrombus of inferior vena cava in patients with renal cell carcinoma - clinical and oncological outcome of 50 patients after surgery.

Authors:  Daniel Claudius Vergho; Andreas Loeser; Arkadius Kocot; Martin Spahn; Hubertus Riedmiller
Journal:  BMC Res Notes       Date:  2012-06-01

8.  Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.

Authors:  Chun-Hua Lin; He-Jia Yuan; Ke Wang; Ji-Tao Wu; Qing-Zuo Liu; Sheng-Qiang Yu; Chang-Ping Men; Zhen-Li Gao; Jiahui Wang
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

9.  Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.

Authors:  Yushi Zhang; Yongqiang Li; Jianhua Deng; Zhigang Ji; Hongyan Yu; Hanzhong Li
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

10.  Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.

Authors:  Takeshi Ujike; Motohide Uemura; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Yasushi Miyagawa; Norio Nonomura
Journal:  Anticancer Drugs       Date:  2016-11       Impact factor: 2.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.